ERNA

8-K - Ernexa Therapeutics Inc. (0000748592) (Filer)

Live video webcast with Sanjeev Luther, President and Chief Executive Officer; Dr. Christopher Rohde, developer of the technology underlying Ernexa’s platform and member of Ernexa’s Scientific Advisory Board; and Dr. Robert Pierce, Chief Scientific Officer, on Thursday, October 15th at 4:00 PM ET Register here CAMBRIDGE, Mass., Oct. 12, 2026 (GLOBE NEWSWIRE) --  Ernexa Therapeutics (NASDAQ:ERNA), an industry innovator developing novel cell therapies for the treatment of advanced cancers, today announced that Sanjeev Luther, President and Chief Executive Officer; Dr. Christopher Rohde, member of Ernexa’s Scientific Advisory Board, and developer of the technology underlying Ernexa’s platfo

CAMBRIDGE, Mass., Oct. 06, 2026 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (NASDAQ:ERNA), an industry innovator developing novel cell therapies for the treatment of advanced cancers, today announced that new preclinical data from its lead oncology program, ERNA-101, have been selected for a Flash Talk presentation at the Next-Generation Cancer Therapeutics meeting, co-hosted by Nature Conferences and The University of Texas MD Anderson Cancer Center. The meeting will take place October 6–8, 2026, on MD Anderson’s campus in Houston, Texas. The presentation will highlight ERNA-101’s potential to address a fundamental challenge in ovarian cancer: the immunosuppressive tumor microenvironment tha

CEO Discusses How Addition of Accomplished Oncology Drug Developer Strengthens Ernexa Ahead of Clinical Development Following ERNA-101 Data Demonstrating Complete Tumor Clearance and 100% Survival in Combination with anti-PD-1 Discussion Highlights ERNA-101’s Near-Term Milestones and Broader Potential Across Difficult-to-Treat Solid Tumors Access the Ernexa CEO Corner here  CAMBRIDGE, Mass., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (NASDAQ:ERNA), an industry innovator developing novel cell therapies for the treatment of advanced cancers, today released a new installment of its CEO Corner series featuring President and Chief Executive Officer Sanjeev Luther. The discussion

 Repeat-dose GLP toxicology study showed no ERNA-101-related adverse findings across all dose levels tested, including no clinical pathology or histopathology findings; single-dose assessment showed no evidence of acute cytokine release No teratoma formation observed in ERNA-101-treated animals through the six-month tumorigenicity in-life phase, addressing a fundamental safety consideration for an iPSC-derived cell therapy Biodistribution study showed no significant ERNA-101 signal in tumor-free animals or non-tumor tissues, supporting ERNA-101’s tumor-homing delivery strategy Encouraging safety results build on previously reported complete tumor clearance and durable survival in ovarian

Ernexa selected for the Emerging Track, recognizing the Company among emerging innovators in the cell and gene therapy sector President & CEO Sanjeev Luther to deliver an Innovation Spotlight presentation on October 6, 2026, at 1:30 PM Presentation to highlight Ernexa’s focused oncology strategy, beginning with ERNA-101 in platinum-resistant ovarian cancer and its potential for broader expansion across ovarian cancer and other solid tumor indications Differentiated synthetic iMSC platform designed to provide a scalable, off-the-shelf treatment solution without the need for patient-specific cell harvesting ERNA-101 remains on track for planned IND submission in 2026 CAMBRIDGE, Mass., Sep

3 - Ernexa Therapeutics Inc. (0000748592) (Issuer)

Dr. Spiegel brings decades of global clinical development, regulatory and oncology leadership experience, including former Chief Medical Officer roles at Schering-Plough and PTC Therapeutics Appointment further strengthens Ernexa’s Board as the Company advances ERNA-101 toward clinical development CAMBRIDGE, Mass., Sept. 17, 2026 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (NASDAQ:ERNA), an industry innovator developing novel cell therapies for the treatment of advanced cancers, today announced the appointment of Robert J. Spiegel, M.D., FACP, to its Board of Directors. Dr. Spiegel is an accomplished physician, biopharmaceutical executive and drug developer with decades of experience spanni

8-K - Ernexa Therapeutics Inc. (0000748592) (Filer)

8-K - Ernexa Therapeutics Inc. (0000748592) (Filer)

ERNA-201 demonstrated encouraging disease-modifying activity in the industry-standard collagen-induced arthritis model, providing meaningful proof-of-concept for Ernexa's engineered synthetic iMSC platform beyond oncology Positive ERNA-201 findings add to a growing body of preclinical evidence supporting the versatility of Ernexa's synthetic iMSC platform and its ability to deliver engineered therapeutic factors in disease Company is concentrating near-term resources on ERNA-101 while broadening its oncology strategy and advancing next-generation iMSC candidates across additional high-need cancer indications ERNA-201 remains an important platform asset with demonstrated preclinical proof

President and CEO Sanjeev Luther to present on Wednesday, September 16, 2026, at 12:00 p.m. ET Management available for one-on-one meetings with investors during the conference CAMBRIDGE, Mass., Sept. 14, 2026 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (NASDAQ:ERNA), an industry innovator developing novel cell therapies for the treatment of advanced cancers, today announced that Sanjeev Luther, President and Chief Executive Officer, will present at the H.C. Wainwright 28th Annual Global Investment Conference, being held September 14–16, 2026, in New York City. During the presentation, Mr. Luther will provide an overview of Ernexa’s focused oncology strategy and recent progress with ERNA-10

4 - Ernexa Therapeutics Inc. (0000748592) (Issuer)

4 - Ernexa Therapeutics Inc. (0000748592) (Issuer)

4 - Ernexa Therapeutics Inc. (0000748592) (Issuer)

4 - Ernexa Therapeutics Inc. (0000748592) (Issuer)

4 - Ernexa Therapeutics Inc. (0000748592) (Issuer)

4 - Ernexa Therapeutics Inc. (0000748592) (Issuer)

3 - Ernexa Therapeutics Inc. (0000748592) (Issuer)

Nine CEOs. Nine investment stories. 60 seconds each to answer the question that matters most to investors: Why now?On-demand video series gives investors rapid access to company leadership, recent milestones, upcoming catalysts and the opportunities management believes investors should be watching todayAccess on demand conference here FRENCHTOWN, NJ / ACCESS Newswire / August 27, 2026 / JTC Team ("JTC"), a fully integrated corporate communications and investor relations firm, today announced the release of its Virtual Investor "Why Now" On-Demand Conference, featuring a fast-paced series of 60-second presentations from the CEOs of nine publicly traded companies.The premise is simple: Why sho

Video webcast now available here CAMBRIDGE, Mass., Aug. 27, 2026 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (NASDAQ:ERNA), an industry innovator developing novel cell therapies for the treatment of advanced cancer and autoimmune disease, today announced that it participated in the Virtual Investor "Why Now" on-demand conference. During the webcast, Sanjeev Luther, President and Chief Executive Officer of Ernexa Therapeutics, presented the Company’s investment thesis and highlighted why he believes now is a pivotal time for Ernexa. The pitch discusses the Company’s planned transition into a clinical-stage biotechnology company, with lead candidate ERNA-101 advancing toward a planned Investig

Seasoned biotechnology founder, public company CFO and corporate strategist brings more than 25 years of leadership in oncology, capital markets, M&A and corporate governance  Appointment further strengthens leadership team at a pivotal inflection point as Company positions ERNA-101 for planned IND submission in Q3 2026 and Phase 1 clinical study initiation in the Q4 2026 CAMBRIDGE, Mass., Aug. 10, 2026 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (NASDAQ:ERNA), an industry innovator developing novel cell therapies for the treatment of advanced cancer and autoimmune disease, today announced the appointment of David Polinsky to its Board of Directors, further strengthening the Company's leader

10-Q - Ernexa Therapeutics Inc. (0000748592) (Filer)

CEO Discusses Why the Future of Cancer Treatment May Belong to Combination Approaches and How ERNA-101 Was Designed to Turn Immunologically "Cold" Tumors Into Targets for the Immune System Video Showcases Differentiated Off-the-Shelf Cell Therapy Platform, Independent Validation of Complete Tumor Clearance in Preclinical Studies and Continued Execution Toward Planned IND Submission in Q3 2026 Access the Ernexa CEO Corner here  CAMBRIDGE, Mass., July 24, 2026 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (NASDAQ:ERNA), an industry innovator developing novel cell therapies for the treatment of advanced cancer and autoimmune disease, today released a new installment of its CEO Corner series fea

DENVER, July 15, 2026 (GLOBE NEWSWIRE) -- (247marketnews.com) – Today’s announcements from NeOnc Technologies (NASDAQ:NTHI), Ernexa Therapeutics (NASDAQ:ERNA), and VivoSim Labs (NASDAQ:VIVS) highlight three distinct pathways to potential value creation. NeOnc Technologies NeOnc Technologies (NASDAQ:NTHI) announced that it has received written feedback from the U.S. Food and Drug Administration regarding the chemistry, manufacturing, and controls (CMC) development program for its lead drug candidate, NEO212, a novel temozolomide-perillyl alcohol conjugate being developed for malignant brain tumors and other central nervous system cancers. Rather than proceeding with its scheduled Type B